Analysis of molecular and clinical parameters of 4-year
adalimumab therapy in psoriatic patients

Dominika Wcisło-Dziadecka; Beniamin Grabarek; Celina Kruszniewska-Rajs; Andrzej Swinarew; Krzysztof Jasik; Beata Rozwadowska; Agata Krawczyk

doi:10.5114/ada.2020.100484

eISSN: 2299-0046
ISSN: 1642-395X

Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii

Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

5/2020
vol. 37

Send email

Copy url:

abstract:

Original paper

Analysis of molecular and clinical parameters of 4-year adalimumab therapy in psoriatic patients

Dominika Wcisło-Dziadecka

¹

,

Beniamin Grabarek

^{2, 3, 4}

,

Celina Kruszniewska-Rajs

²

,

Andrzej S. Swinarew

^{5, 6}

,

Krzysztof Jasik

⁷

,

Beata Rozwadowska

^{8, 9}

,

Agata Krawczyk

¹⁰

Department of Cosmetology, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia in Katowice, Poland
Department of Molecular Biology, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia in Katowice, Poland
Department of Histology, Cytophysiology and Embryology in Zabrze, Faculty of Medicine in Zabrze, University of Technology in Katowice, Poland
District Hospital, Chrzanow, Poland
Faculty of Science and Technology in Chorzow, University of Silesia in Katowice, Poland
Department of Swimming and Water Rescue, Institute of Sport Science, The Jerzy Kukuczka Academy of Physical Education, Katowice, Poland
Department of Pathology, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia in Katowice, Poland
Provincial Sanitary and Epidemiological Station, Katowice, Poland
Silesian Medical College in Katowice, Poland
Department of Nutrigenomics and Bromatology, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia in Katowice, Poland

Adv Dermatol Allergol 2020; XXXVII (5): 736-745

DOI: https://doi.org/10.5114/ada.2020.100484

Online publish date: 2020/11/07

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Wcisło-Dziadecka D, Grabarek B, Kruszniewska-Rajs C, et al. Analysis of molecular and clinical parameters of 4-year
adalimumab therapy in psoriatic patients. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii. 2020;37(5):736-745. doi:10.5114/ada.2020.100484.

APA

Wcisło-Dziadecka, D., Grabarek, B., Kruszniewska-Rajs, C., Swinarew, A. S., Jasik, K.,  & Rozwadowska, B. et al. (2020). Analysis of molecular and clinical parameters of 4-year
adalimumab therapy in psoriatic patients. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, 37(5), 736-745. https://doi.org/10.5114/ada.2020.100484

Chicago

Wcisło-Dziadecka, Dominika, Beniamin Grabarek, Celina Kruszniewska-Rajs, Andrzej S Swinarew, Krzysztof Jasik, Beata Rozwadowska,  and Agata Krawczyk. 2020. "Analysis of molecular and clinical parameters of 4-year
adalimumab therapy in psoriatic patients". Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii 37 (5): 736-745. doi:10.5114/ada.2020.100484.

Harvard

Wcisło-Dziadecka, D., Grabarek, B., Kruszniewska-Rajs, C., Swinarew, A., Jasik, K., Rozwadowska, B.,  and Krawczyk, A. (2020). Analysis of molecular and clinical parameters of 4-year
adalimumab therapy in psoriatic patients. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, 37(5), pp.736-745. https://doi.org/10.5114/ada.2020.100484

MLA

Wcisło-Dziadecka, Dominika et al. "Analysis of molecular and clinical parameters of 4-year
adalimumab therapy in psoriatic patients." Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, vol. 37, no. 5, 2020, pp. 736-745. doi:10.5114/ada.2020.100484.

Vancouver

Wcisło-Dziadecka D, Grabarek B, Kruszniewska-Rajs C, Swinarew A, Jasik K, Rozwadowska B et al. Analysis of molecular and clinical parameters of 4-year
adalimumab therapy in psoriatic patients. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii. 2020;37(5):736-745. doi:10.5114/ada.2020.100484.

Introduction
Through interaction with receptors TNFR1 and TNFR2, TNF-a activates a signal path, which exacerbates an inflammatory process, constituting an inseparable element of psoriasis.

Aim
To evaluate changes in the expression of TNF-a, TNFR1, TNFR2 during the 4-year-long adalimumab therapy in psoriatic patients, searching for the correlation between molecular and clinical markers. In addition, the role of miRNAs was analysed.

Material and methods
Whole blood and serum samples of psoriatic patients treated with adalimumab constituted material for the study. Changes in the expression of TNF-a and its receptors were evaluated with the use of the RTqPCR method and MALDI ToF mass spectroscopy, PASI, BSA, DAS28 indexes were used for the clinical analysis of the patients, while the role of miRNA molecules was determined basing on microrna.org database

Results
Different TNF-a expression patterns were determined in patients with observed resistance to the medicine. We found that there is a correlation between the molecular markers of an inflammatory process and the clinical indexes. The bioinformatic analysis indicates the potential role of miRNAs in the regulation of expression of the analysed genes. Changes in the profile of TNF-a during adalimumab therapy are significantly determined by the individual variability and susceptibility to the biological medicine or its loss.

Conclusions
TNF-a seems to be a useful marker to evaluate the efficacy of therapy and occurring resistance to the medicine. A complex mechanism for the regulation of the analysed gene expression was underlined, which involved the potential role of miRNAs.

keywords:

Analysis of molecular and clinical parameters of 4-year adalimumab therapy in psoriatic patients

Dominika Wcisło-Dziadecka 1 , Beniamin Grabarek 2, 3, 4 , Celina Kruszniewska-Rajs 2 , Andrzej S. Swinarew 5, 6 , Krzysztof Jasik 7 , Beata Rozwadowska 8, 9 , Agata Krawczyk 10

tumor necrosis factor a, treatment personalisation, miRNA, anti-TNF therapy, psoriasis

Dominika Wcisło-Dziadecka

¹

,

Beniamin Grabarek

^{2, 3, 4}

,

Celina Kruszniewska-Rajs

²

,

Andrzej S. Swinarew

^{5, 6}

,

Krzysztof Jasik

⁷

,

Beata Rozwadowska

^{8, 9}

,

Agata Krawczyk

¹⁰